ATE433454T1 - Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors - Google Patents

Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Info

Publication number
ATE433454T1
ATE433454T1 AT05854388T AT05854388T ATE433454T1 AT E433454 T1 ATE433454 T1 AT E433454T1 AT 05854388 T AT05854388 T AT 05854388T AT 05854388 T AT05854388 T AT 05854388T AT E433454 T1 ATE433454 T1 AT E433454T1
Authority
AT
Austria
Prior art keywords
optionally substituted
alkyl
cycloalkyl
hydrogen
halo
Prior art date
Application number
AT05854388T
Other languages
English (en)
Inventor
Martin Clasby
Samuel Chackalamannil
Bernard Neustadt
Xiaobang Gao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE433454T1 publication Critical patent/ATE433454T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05854388T 2004-12-21 2005-12-19 Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors ATE433454T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63802804P 2004-12-21 2004-12-21
PCT/US2005/045658 WO2006068954A2 (en) 2004-12-21 2005-12-19 PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
ATE433454T1 true ATE433454T1 (de) 2009-06-15

Family

ID=36602229

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854388T ATE433454T1 (de) 2004-12-21 2005-12-19 Pyrazoloä1,5-aüpyrimidine als antagonisten des adenosin-a2a-rezeptors

Country Status (10)

Country Link
US (1) US7741318B2 (de)
EP (1) EP1836205B1 (de)
JP (1) JP2008524330A (de)
CN (1) CN101119998A (de)
AT (1) ATE433454T1 (de)
CA (1) CA2591125A1 (de)
DE (1) DE602005014891D1 (de)
ES (1) ES2327145T3 (de)
MX (1) MX2007007604A (de)
WO (1) WO2006068954A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) * 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2008027220A2 (en) * 2006-08-28 2008-03-06 Schering Corporation Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3, 3a-dihydropyrazol0 [1, 5-a] pyrimidin-7-yl) -amino derivatives
JP5214799B2 (ja) * 2008-04-07 2013-06-19 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤としての化合物および組成物
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2210891A1 (de) 2009-01-26 2010-07-28 Domain Therapeutics Neue Adenosin-Rezeptorliganden und Verwendungen davon
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
CN101906105B (zh) * 2009-06-08 2013-01-16 河北医科大学 吡唑并[1，5-a]嘧啶酮衍生物及其药物组合物以及其用途
WO2011061754A1 (en) * 2009-11-18 2011-05-26 Council Of Scientific & Industrial Research A novel 3-substituted 7-imino-2-thioxo-3, 7-dihydro-2h-thiazolo [4,5-di pyrimidin-6-yl - and process for preparation thereof
PH12012501643A1 (en) * 2010-02-26 2017-07-19 Mitsubishi Tanabe Pharma Corp Pyrazolopyrimidine compounds and their use as pde 10 inhibitors
AU2011260323A1 (en) * 2010-06-04 2012-11-15 F. Hoffmann-La Roche Ag Aminopyrimidine derivatives as LRRK2 modulators
US20140288052A1 (en) * 2011-10-20 2014-09-25 GlaxoSmithKline, LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
RU2015143517A (ru) * 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
CN103626776B (zh) * 2013-12-05 2017-02-15 北京师范大学 吡唑并[1,5‑a]嘧啶氮芥衍生物及其制备方法和肿瘤治疗应用
US10913744B2 (en) * 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
KR20250174699A (ko) 2018-10-30 2025-12-12 크로노스 바이오, 인코포레이티드 Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
JP2022507734A (ja) 2018-11-20 2022-01-18 メルク・シャープ・アンド・ドーム・コーポレーション 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用
AR117164A1 (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
CN112921405B (zh) * 2019-12-05 2023-06-27 成都先导药物开发股份有限公司 一种合成On-DNA吡唑并[1，5-a]嘧啶化合物的方法
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
WO2026089952A1 (en) * 2024-10-21 2026-04-30 International Flavors & Fragrances Inc. Novel flavor modulating compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2057089A1 (en) * 1990-12-07 1992-06-08 Eric E. Allen Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin ii antagonists
US5571813A (en) * 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
WO1998042711A1 (en) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
YU23602A (sh) * 1999-09-30 2004-09-03 Neurogen Corporation Amino supstituisani pirazolo /1,5/a/-1,5-pirimidini i pirazolo /1,5-a/-1,3,5-triazini
DE60313872T2 (de) * 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
JP4564485B2 (ja) * 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2004092171A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists

Also Published As

Publication number Publication date
US7741318B2 (en) 2010-06-22
US20060135526A1 (en) 2006-06-22
EP1836205A2 (de) 2007-09-26
DE602005014891D1 (de) 2009-07-23
CA2591125A1 (en) 2006-06-29
EP1836205B1 (de) 2009-06-10
JP2008524330A (ja) 2008-07-10
WO2006068954A2 (en) 2006-06-29
WO2006068954A3 (en) 2006-12-07
HK1108882A1 (en) 2008-05-23
MX2007007604A (es) 2007-08-02
ES2327145T3 (es) 2009-10-26
CN101119998A (zh) 2008-02-06

Similar Documents

Publication Publication Date Title
DE602005014891D1 (de) PYRAZOLOÄ1,5-AÜPYRIMIDINE ALS ANTAGONISTEN DES ADENOSIN-A2a-REZEPTORS
ATE466860T1 (de) Cgrp-rezeptorantagonisten
NO20062894L (no) 6-alkenyl og 6-fenylalkylsubstituert 2-kinolinoner og 2-kinoksalinoner som poly(adp-ribose)polymeraseinhibitorer
ATE464287T1 (de) Cyclohexyl-sulphone als gamma-sekretase- inhibitoren
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
DE602004006166D1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
DE60335731D1 (de) Sulfonamide, sulfamate und sulfamide als gamma-secretase-hemmer
ATE302775T1 (de) Carbolinderivate
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
ATE453639T1 (de) Phenylsubstituierte pyrimidinverbindungen zur verwendung als kinasehemmer
DE60328010D1 (de) Heterocyclische verbindungen
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
NO20071922L (no) Indazoler, benzisokazoler og benzinsotiazoler og anvendelse derav som ostrogene midler
ATE503755T1 (de) Cgrp-rezeptorantagonisten
NO20054340L (no) Nye sammenkoplede heterocykler og deres anvendelse
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
MXPA05010651A (es) Compuestos de pirazol.
ATE384708T1 (de) Piperazinderivate als aktivitätsmodulatoren der chemokinrezeptoren
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties